PIQUR Logo
X
Credits

Corporate Design, Web Design, Web Concept and Code:
SchwizerSchlatter GmbH, St.Gallen

Content:
IRF Communications AG, Zürich

Photography:
Till Forrer Photography, Zürich

PIQUR Logo
X
Disclaimer

No warranty and no liability
The material provided in this site is presented solely to improve public access to information about PIQUR Therapeutics AG.
PIQUR Therapeutics AG will make reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations, expressed or implied, as to its accuracy or completeness. PIQUR Therapeutics AG will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in this site.
PIQUR Therapeutics AG may change the content of this site including the terms that govern the use of this site at any time without prior notice but does not assume any responsibility to update the information provided herein.

Forward looking information
Some of the statements on this site are forward looking. Such statements are inherently subject to known and unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of PIQUR Therapeutics AG and affiliates to be materially different from those expected or anticipated in the forward-looking statements.

PIQUR Therapeutics AG has no responsibility to update the forward-looking statements contained in this site to reflect events or circumstances occurring after the date of publication. You must not rely on this information for investment decisions.

Links to third party sites
Links to third party sites are provided for convenience only, and the inclusion of any links does not imply endorsement by PIQUR Therapeutics AG. The linked sites are not under control of PIQUR Therapeutics AG, and PIQUR Therapeutics AG disclaims any liability for all third party information and the use of it.

Restrictions on use and submissions
The contents of this site are owned and controlled by PIQUR Therapeutics AG. No use of any of these may be made without the prior written consent of PIQUR Therapeutics AG. All submissions communicated to PIQUR Therapeutics AG through this site shall be and remain PIQUR Therapeutics AG’s property. PIQUR Therapeutics AG will be entitled to use your submission for any commercial or other purpose whatsoever without paying any compensation to you. PIQUR Therapeutics AG will be under no obligation to treat your submission as confidential nor to respond to it. The pictures displayed on this website are subject to copyrights and may not be downloaded, copied, distributed or otherwise be used without prior permission of PIQUR Therapeutics AG.

Applicable law and jurisdiction
These terms shall be construed, enforced and performed in accordance with the substantive laws of Switzerland, without reference to the principles of conflicts of laws. The place of jurisdiction is Basel, Switzerland. PIQUR Therapeutics AG makes no representation that any information, materials or functions included are appropriate for use in any other jurisdiction. If you access this site you do so on your own initiative and are responsible for compliance with applicable local laws and regulations.

Address
Directions by car
Directions from railway station Basel Bad Bf
Directions from the railway station Basel SBB
How to find us
Show Map
Address

Address:
PIQUR Therapeutics AG
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland
T +41 61 633 29 29
info@piqur.com

Media Contact:
IRF Communications AG
Daniel Piller, Partner
Raemistrasse 4
P.O. Box
CH-8024 Zürich
Switzerland
daniel.piller@irfcom.ch
www.irfcom.ch

X
Directions by car

Highway A2 exit 1, along in direction Stücki/Kleinhüningen, you can drive up the ramp of the big grey building called Stücki Businesspark (next to the COOP gas station) and park right in front of the building or on the parking below.

X
Directions from railway station Basel Bad Bf

Bus no. 36 in direction Kleinhüningen, get off at bus-station «Hochbergerstrasse» (approx. 4 min.), follow driveway Hochbergerstrasse, after 150m on your right hand side you will see a big grey building called Stücki Business Park, go up the ramp and you find the entrance «C»

X
Directions from the railway station Basel SBB

Tram no. 2 in direction Eglisee, get off at tram-station «Basel Badischen Bahnhof» (approx. 10 min.), change and take bus no. 36 in direction Kleinhüningen, bus-stop «Hochbergerstrasse» (approx. 5 min.), follow driveway Hochbergerstrasse, after 150m on your right hand side you will see a big grey building called Stücki Business Park, go up the ramp and you find the entrance «C».

X
How to find us

PIQUR is located close to the centre of Basel on the north bank of the River Rhine, a few minutes from the borders of France and Germany. It is easily accessible by public transport from the two main railway stations and the airport.

The premises of PIQUR Therapeutics AG are located in the Technology Park Basel in the Stücki Business Park.

X
Contact
Vision
Management
Executive Directors
Board of Directors
Advisory Boards
Careers
Vision

PIQUR’s vision is to improve the lives of cancer patients with breakthrough medicines. Despite significant advances in the cancer therapies, there remains a high unmet medical need for therapies that not only prolong patients’ survival but also significantly improve quality of life.

PIQUR was founded in August 2011 by Vladimir Cmiljanovic, Bernd Giese, Matthias Wymann, Andreas Emmenegger and Ralf Rosenow as a spin-off of the University of Basel. The company focuses on the discovery and development of innovative anti-cancer drugs based on the inhibition of the PI3K (phosphoinositide 3-kinase) and mTOR (mammalian target of rapamycin) pathways, one of the most promising research areas in oncology and clinically validated drug targets. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.

Management

+
-
Dr. Vladimir Cmiljanović – CEO

Vladimir Cmiljanović, Chief Executive Officer, has hands-on experience in the range of chemistry disciplines (organic, medicinal, analytical & biochemistry) essential to the discovery of PI3K-Akt-mTOR pathway products. Vladimir built...

Vladimir Cmiljanović, Chief Executive Officer, has hands-on experience in the range of chemistry disciplines (organic, medicinal, analytical & biochemistry) essential to the discovery of PI3K-Akt-mTOR pathway products. Vladimir built up the team of well-known and recognized experts from the field and is leader of the team creating PIQUR’s industry leading next generation PI3K agents. For his scientific contribution in PI3K-AKT-mTOR research field he was awarded in 2009 with the Camille and Henry Dreyfus Award of the University of Basel and in 2011 with the Novartis and University of Basel Excellence Scholarship for Life Sciences. In 2014, Vladimir was the winner of the Northwest Switzerland Young Entrepreneurs’ Award (Jungunternehmerpreis Nordwestschweiz) and in 2015, PIQUR won the prestigious Swiss Economic Award.

+
-
Dr. Melanie Rolli – CMO

Melanie Rolli, Chief Medical Officer, brings more than a decade of industry experience and senior responsibilities in global development, medical affairs and patient safety. She joins PIQUR from Novartis...

Melanie Rolli, Chief Medical Officer, brings more than a decade of industry experience and senior responsibilities in global development, medical affairs and patient safety. She joins PIQUR from Novartis Pharma, where she held various positions with increasing responsibilities over the last 14 years, most recently as Global Head Medical Safety. Prior to joining Novartis, she worked as a medical doctor at the University Hospital in Mannheim and as a basic researcher in academic settings in Germany and at the Scripps Research Institute, USA.

+
-
Dr. Doriano  Fabbro – CSO

Doriano  Fabbro, Chief  Scientific  Officer,  received  his  Ph.D.  in cell  biology  and biochemistry  at  the  University of Basel, where he worked afterwards for 12 years as Group Leader in...

Doriano  Fabbro, Chief  Scientific  Officer,  received  his  Ph.D.  in cell  biology  and biochemistry  at  the  University of Basel, where he worked afterwards for 12 years as Group Leader in Molecular Tumor Biology. In 1991, he joined the Oncology Group of Ciba-Geigy Basel. After the merger of Ciba-Geigy with Sandoz in 1996 he served at Novartis as Head of Kinase Biology until 2012. Doriano has contributed to the discovery and development of various protein kinase inhibitors for the treatment of cancer; e.g. Midostaurin®, Glivec®, Afinitor®, and Tasigna®. Doriano is author in more than 200 publications and numerous patents in the area of protein kinases regulation, structure, screening and drug discovery. He has been honored with the Novartis Oncology President’s Award (2005).

+
-
Hervé Girsault – CBO

Hervé Girsault, Chief Business Officer, has more than 15 years of accomplishments in the life sciences industry. His professional experience includes senior management positions at Novartis, such as Global...

Hervé Girsault, Chief Business Officer, has more than 15 years of accomplishments in the life sciences industry. His professional experience includes senior management positions at Novartis, such as Global Head of Business Development and M&A for Novartis Consumer Health, Worldwide Head of Partnering at Novartis Pharma, CEO of Novartis Nutrition Benelux. He was also the CEO of CCBR-Synarc, a leader in healthcare services and CEO of Gerber Products Company in France, a leader in infant nutrition.

+
-
Martin Gasser – CFO

Martin Gasser is a highly experienced Chief Financial Officer (CFO) with background in international technology firms. In addition, Martin Gasser is engaged as non-executive board member as well as...

Martin Gasser is a highly experienced Chief Financial Officer (CFO) with background in international technology firms. In addition, Martin Gasser is engaged as non-executive board member as well as finance expert for several SMEs. Martin Gasser currently serves as Managing Director of Reichle Holding AG. Prior to that, he held the position of CFO at Reichle & De-Massari Holding AG.

Executive Directors

+
-
Prof. Dr. Richard Herrmann – Medical Director Oncology

Richard Herrmann is the Chief Medical Officer ad interim and oversees all clinical studies at PIQUR. Richard is also a Member of the Oncology Advisory Board, and previously served...

Richard Herrmann is the Chief Medical Officer ad interim and oversees all clinical studies at PIQUR. Richard is also a Member of the Oncology Advisory Board, and previously served as Chief Medical Officer of PIQUR Therapeutics until 2015. From 1991 to 2011, he was Head of the Division of Oncology at the University Hospital Basel, Switzerland, as well as Professor of Medicine at the University of Basel. Additional positions included President of SAKK (Swiss Group for Clinical Cancer Research) from 2004 to 2010, President of Oncosuisse, the Swiss Federation Against Cancer, from 2009 to 2012 and Head of the Department of Clinical Research at Basel University Hospital from 2011 to 2013.

+
-
Dr. Paul Hebeisen

Head Drug Discovery, has 28 years of experience in medicinal chemistry at F. Hoffmann-La Roche AG. He has served in various positions most notably as group leader in chemistry in...

Head Drug Discovery, has 28 years of experience in medicinal chemistry at F. Hoffmann-La Roche AG. He has served in various positions most notably as group leader in chemistry in the discovery of novel antiinfectives (e.g.  Zevtera®).He was chemistry leader in a collaboration with Sumitomo in the search for novel carbapenems overcoming resistance to marketed agents. With the termination of antibacterial research at Roche he switched to metabolic research and contributed successfully to the introduction of appetite suppressants as well as anti-dislipidemics into the clinic.

+
-
Dr. Robert Ettlin

Head Preclinical Safety & Toxicology. After some years in toxicological pathology at F. Hoffmann La Roche Ltd. he joined Sandoz Ltd. in Basel, where he advanced to Head of...

Head Preclinical Safety & Toxicology. After some years in toxicological pathology at F. Hoffmann La Roche Ltd. he joined Sandoz Ltd. in Basel, where he advanced to Head of Toxicology and later Head of Development Operations Switzerland. In between he served as Head of Preclinical Development and member of the committee of Novartis Pharma in Japan.

+
-
Dr. Beda Fischer

Head Quality Assurance, brings over 32 years of experience in Analytical Research and Development (ARD), Quality Control (QC) and Quality Assurance (QA) in the field of Drug Substance, Drug...

Head Quality Assurance, brings over 32 years of experience in Analytical Research and Development (ARD), Quality Control (QC) and Quality Assurance (QA) in the field of Drug Substance, Drug Product and Biotech Products. He is former Head of ARD in Ciba Geigy, and Global Head of QA in Technical Research and Development of Novartis (1997-2011).

+
-
Dr. Marc Lang

Head Medicinal Chemistry, has more than 30 years of experience in medicinal chemistry, of which some 20 years in Oncology and Immunology. He has contributed to three multi-billion Novartis...

Head Medicinal Chemistry, has more than 30 years of experience in medicinal chemistry, of which some 20 years in Oncology and Immunology. He has contributed to three multi-billion Novartis compounds on market (Femara®, Reyataz® and Tasigna®), and five promising compounds in clinical trials. Until October 2012, he was Head of Medicinal Chemistry for Oncology research programs at Novartis Pharma AG.

Board of Directors

+
-
Prof. Dr. Bernd Giese, Chairman

Bernd Giese is Co-Founder and Chairman of the Board of Directors of PIQUR. Bernd co-directed the synthesis and the bioorganic chemistry of the drugs that are substance of PIQUR....

Bernd Giese is Co-Founder and Chairman of the Board of Directors of PIQUR. Bernd co-directed the synthesis and the bioorganic chemistry of the drugs that are substance of PIQUR.

Due to his contribution in synthetic radical chemistry, electron transfer in DNA and peptides, and investigation of cellular signal transduction pathways using chemical compounds, Bernd is recipient of numerous international awards in chemistry including Karl-Winnacker Award 1976, Carl-Duisberg Award 1977, Gottfried-Wilhelm- Leibniz Award 1987, Merck-Schuchardt Award 1988, Tetrahedron Prize for Creativity in Organic Chemistry 2005, Emil Fischer Medal 2006, Norris Award 2009 and Paracelsus Award 2012.

+
-
Dr. Vladimir Cmiljanovic

Vladimir Cmiljanovic is Co-Founder, Chief Executive Officer, and Vice-Chairman of the Board of Directors of PIQUR. Vladimir has hands-on experience in the range of chemistry disciplines (organic, medicinal, analytical...

Vladimir Cmiljanovic is Co-Founder, Chief Executive Officer, and Vice-Chairman of the Board of Directors of PIQUR. Vladimir has hands-on experience in the range of chemistry disciplines (organic, medicinal, analytical & biochemistry) essential to the discovery of PI3K-Akt-mTOR pathway products.

Vladimir built up the team of well-known and recognized experts from the field and is leader of the team creating PIQUR’s industry leading next generation PI3K agents.

For his scientific contribution in PI3K-AKT-mTOR research field he was awarded in 2009 with the Camille and Henry Dreyfus Award of the University of Basel and in 2011 with the Novartis and University of Basel Excellence Scholarship for Life Sciences. In 2014, Vladimir was the winner of the Northwest Switzerland Young Entrepreneurs’ Award (Jungunternehmerpreis Nordwestschweiz).

+
-
Prof. Dr. Matthias Wymann

Matthias Wymann is Co-Founder, member of the Board of Directors of PIQUR and Professor at the University of Basel. Matthias is one of the most knowledgeable and experienced scientists...

Matthias Wymann is Co-Founder, member of the Board of Directors of PIQUR and Professor at the University of Basel. Matthias is one of the most knowledgeable and experienced scientists in this research area. He discovered the first PI3K inhibitor (Wortmannin) and his genetic and in vivo model studies explained the role of PI3Kgamma in inflammation, allergy, cardiovascular diseases and obesity.

In 2005 he was finalist of the European Descartes prize for his development of PI3K drugs in inflammatory disease.

Over many years, Matthias assisted several large pharma companies with their PI3K-Akt-mTOR pathway inhibitor discovery and development programs.

+
-
Andreas Emmenegger

Andreas Emmenegger is Co-Founder and Member of the Board of Directors of PIQUR. Andreas serves as CFO and Entrepreneur at Molecular Partners AG since 2007. Prior to that, he...

Andreas Emmenegger is Co-Founder and Member of the Board of Directors of PIQUR. Andreas serves as CFO and Entrepreneur at Molecular Partners AG since 2007. Prior to that, he was CFO of Glycart biotechnology where he had a leading role in the successful CHF 235 million trade sale to the Roche Group in 2005 and he was Head of Strategic Alliance Finance (Genentech) for Roche Headquarters, Basel, Switzerland.

Andreas has over 15 years of experience as a CFO of several public and private multinational companies raising over CHF 200 million equity through public and private offerings, including one IPO.

Further, he has over 10 years of international industry experience in banking, capital markets, M&A, human resources and retail business. Andreas holds an Executive MBA degree from IESE Business School, Barcelona.

+
-
Dr. Guido Magni

Guido Magni is a member of the Board of Directors of PIQUR. Guido is currently Venture Partner at Versant Ventures. In 1993, he became Therapeutic Area Head CNS at...

Guido Magni is a member of the Board of Directors of PIQUR. Guido is currently Venture Partner at Versant Ventures. In 1993, he became Therapeutic Area Head CNS at Roche Basel, where he was promoted in 1995 to Head of the Medical Science Group in the development department. He has kept this position for 12 years. The Medical Science at Roche was made up of different groups, including all the therapeutic areas, clinical pharmacology, biostatistics, safety risk management and project management for early projects.

During his tenure as head of medical science, Roche registered 15 NCEs/ NBEs. When he left Roche in 2008 he joined Versant Ventures where he works as a partner in the Basel office.

Guido is currently also a member of the Board of Gensight Biologics, Biotie and AM Pharma.

Advisory Boards

Oncology Advisory Board
Prof. Dr. Josep Tabernero

Chairman of the Oncology Advisory Board, is Head of the Medical Oncology Department and Head of the Gastrointestinal Tumors and Phase I Unit at the Vall d’Hebron University Hospital in Barcelona, Spain. Tabernero is actively involved in molecular targeted therapies and related translational research, with a special focus on EGFR family and PI3K-Akt-mTOR pathway inhibitors. He was elected President of the European Society for Medical Oncology (ESMO) for the 2018-2019 period; ESMO is the leading European cancer organization.

Prof. Dr. Hilary Calvert

Member of the Oncology Advisory Board, has a longstanding interest in cancer drug discovery and development and has been closely involved with the development of Carboplatin®, Raltitrexed®, Pemetrexed® and Rucaparib. He is the Director of Anticancer Drug Discovery and Development and Professor of Cancer Therapeutics at University College London Partners and is based at the UCL Cancer Institute where his role is to foster clinical programs of new drug trials in cancer and drug discovery initiatives.

Prof. Dr. Richard Herrmann

Member of the Oncology Advisory Board, Chief Medical Officer of PIQUR Therapeutics until 2015. From 1991 to 2011, he was Head of the Division of Oncology at the University Hospital Basel, Switzerland, as well as Professor of Medicine at the University of Basel. Additional positions included President of SAKK (Swiss Group for Clinical Cancer Research) from 2004 to 2010, President of Oncosuisse, the Swiss Federation Against Cancer, from 2009 to 2012 and Head of the Department of Clinical Research at Basel University Hospital from 2011 to 2013.

Scientific Advisory Board
Prof. Dr. Roger Williams

Chairman of the Scientific Advisory Board, is Professor at University of Cambridge. His research focuses on developing a detailed structural understanding of the network of interacting pathways involved in phospholipid signalling.

Prof. Dr. Andreas Pfaltz

Member of the Scientific Advisory Board, is Professor of Organic Chemistry at the University of Basel. His research focuses on the development of catalytic methods for organic synthesis, with special emphasis on metal-catalyzed asymmetric reactions

Prof. Dr. Michael N. Hall

Member of the Scientific Advisory Board, joined the Biozentrum of the University of Basel in 1987 where he is currently Professor and former Chair of Biochemistry. He is a world leader in the fields of TOR signalling and cell growth control. In 1991, Hall and colleagues discovered TOR (Target of Rapamycin).

Prof. Dr. Victor Snieckus

Member of the Scientific Advisory Board, Professor and Bader Chair Emeritus at Queen’s University Canada, has made fundamental contributions to synthetic aromatic and heteroaromatic chemistry with significant impact on the discovery and development of medicinal and agrochemical agents.

Prof. Dr. David Spiegel

Member of the Scientific Advisory Board, is Associate Professor of Chemistry and Pharmacology at Yale University. His research focus ranges from synthetic reaction development and natural product synthesis to the construction of functional molecules capable of accomplishing specific biological tasks.

Prof. Dr. Marketa Zvelebil

Member of the Scientific Advisory Board, brings 25 years experience of general bioinformatics but especially of protein structural modelling and ligand docking/QSAR. She is team leader and Reader of Cancer Informatics at the Institute of Cancer Research (ICR), London, in the Breakthrough Breast Cancer division.

Business Advisory
Careers

Working at PIQUR Therapeutics

At PIQUR, we understand that the success of the company is a direct result of the commitment and scientific drive of the whole team. We foster creativity, collaboration and innovation and are looking for dedicated people that share our vision to improve the lives of cancer patients with breakthrough medicines.

Are you a team player, whose scientific curiosity is complemented by an entrepreneurial spirit, focus and persistence? Do you feel motivated to bring innovative medical solutions to the breakthrough?

We encourage you to send your curriculum vitae to info@piqur.com or to apply to any of the open positions matching your skills and experiences.